The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | Phase I trial of copanlisib + nivolumab in patients with Richter’s transformation or transformed FL
In this video, Geoffrey Shouse, DO, PhD, City of Hope, Duarte, CA, gives an overview of a Phase I trial evaluating the safety and efficacy of copanlisib in combination with nivolumab in patients with transformed follicular lymphoma (FL) and Richter’s transformation (RT; NCT03884998). A small subset of patients with RT responded to this combination, and in patients with transformed FL, a promising response rate was observed, although the duration of response (DoR) was shorter. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Speakers Bureau: Beigene, Inc., Kite Pharmaceuticals
Consultancy: Kite Pharmaceuticals
